Bridgebio Pharma, Inc.
SEC CIK 1743881 · BBIO · last insider filing 2026-06-24
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Hassan Fred | Director | filed 2021 - 2026 |
| Daniels Ronald J | Director | filed 2020 - 2026 |
| Homcy Charles J | Director · Chairman of Pharmaceuticals | filed 2019 - 2026 |
| Momtazee James C | Director | filed 2019 - 2026 |
| Mccormick Frank | Director · Chairman of Oncology | filed 2019 - 2026 |
| Aguiar Eric | Director | filed 2019 - 2026 |
| Satvat Ali J. | Director | filed 2019 - 2026 |
| Dachille Douglas A. | Director | filed 2021 - 2026 |
| Lo Andrew | Director | filed 2020 - 2026 |
| Cook Jennifer E. | Director | filed 2019 - 2026 |
| Valantine Hannah | Director | filed 2021 - 2026 |
| Ellis Andrea | Director | filed 2021 - 2026 |
| Kumar Neil | Director · See Remarks | filed 2019 - 2026 |
| Scott Randal W. | Director | filed 2020 - 2026 |
| Scheller Richard H | Director · See Remarks | filed 2019 - 2023 |
| Saunders Brent L | Director | filed 2020 - 2022 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Trimarchi Thomas | President and COO | filed 2024 - 2026 |
| Apuli Maricel | Chief Accounting Officer | filed 2025 - 2026 |
| Stephenson Brian C | See Remarks | filed 2019 - 2025 |
| Turtle Cameron | See Remarks | filed 2019 - 2020 |
| Sinha Uma | Chief Scientific Officer | filed 2019 - 2020 |
| Henderson Michael Thomas | See Remarks | filed 2019 - 2020 |
| YAU YI Ching | Chief Accounting Officer | filed 2019 - 2020 |
| Stolz Brian M. | Chief Operating Officer | filed 2019 - 2020 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.